Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
CVAC 
CureVac NV (CVAC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: CVAC (4-star) is a WEAK-BUY. BUY since 99 days. Simulated Profits (54.47%). Updated daily EoD!
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $5.45
1 Year Target Price $5.45
| 2 | Strong Buy |
| 0 | Buy |
| 4 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 84.33% | Avg. Invested days 52 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.20B USD | Price to earnings Ratio 5.3 | 1Y Target Price 5.45 |
Price to earnings Ratio 5.3 | 1Y Target Price 5.45 | ||
Volume (30-day avg) 6 | Beta 2.53 | 52 Weeks Range 2.37 - 5.72 | Updated Date 09/17/2025 |
52 Weeks Range 2.37 - 5.72 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.01 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 37.93% | Operating Margin (TTM) -4959.44% |
Management Effectiveness
Return on Assets (TTM) 23.77% | Return on Equity (TTM) 40.22% |
Valuation
Trailing PE 5.3 | Forward PE 5.24 | Enterprise Value 785074385 | Price to Sales(TTM) 2.36 |
Enterprise Value 785074385 | Price to Sales(TTM) 2.36 | ||
Enterprise Value to Revenue 1.31 | Enterprise Value to EBITDA 2.81 | Shares Outstanding 225172992 | Shares Floating 125869315 |
Shares Outstanding 225172992 | Shares Floating 125869315 | ||
Percent Insiders 57.37 | Percent Institutions 6.52 |
Upturn AI SWOT
CureVac NV
Company Overview
History and Background
CureVac NV was founded in 2000 in Tu00fcbingen, Germany, as a spin-off from the University of Tu00fcbingen. It pioneered mRNA technology for therapeutic and prophylactic applications. Initially focused on cancer therapies, the company expanded to infectious diseases and protein therapies. Significant milestones include the development of mRNA-based COVID-19 vaccine candidates and partnerships with pharmaceutical giants.
Core Business Areas
- mRNA-based Therapeutics: Development of mRNA-based therapies for cancer, infectious diseases, and protein therapies.
- Vaccines: Research, development, and commercialization of mRNA-based vaccines against infectious diseases.
- mRNA Technology Platform: Advancement and licensing of CureVac's proprietary mRNA technology platform.
Leadership and Structure
The company is led by a management board headed by CEO Alexander Zehnder. The board oversees research, development, and commercial operations. The organizational structure includes departments focused on drug discovery, clinical trials, manufacturing, and business development.
Top Products and Market Share
Key Offerings
- CVnCoV (COVID-19 Vaccine Candidate): CureVac's initial COVID-19 vaccine candidate showed lower efficacy than mRNA vaccines from Pfizer/BioNTech and Moderna. It faced regulatory setbacks and was ultimately withdrawn. Competitors: Pfizer/BioNTech (BNTX), Moderna (MRNA), AstraZeneca (AZN), Johnson & Johnson (JNJ).
- Second-Generation COVID-19 Vaccine: CureVac partnered with GSK to develop a second-generation mRNA COVID-19 vaccine based on updated technology. Details on market share or revenue are unavailable pending successful development and commercialization. Competitors: Pfizer/BioNTech (BNTX), Moderna (MRNA).
- Cancer Immunotherapies: CureVac is developing mRNA-based cancer immunotherapies in clinical trials. Market share and revenue data are not yet available due to the early stage of development. Competitors: BioNTech (BNTX), Moderna (MRNA), Merck (MRK).
Market Dynamics
Industry Overview
The mRNA therapeutics and vaccines market is rapidly growing, driven by the success of mRNA COVID-19 vaccines. Key players are investing heavily in research and development. The market is characterized by high competition and innovation.
Positioning
CureVac NV is positioned as a pioneer in mRNA technology but faces strong competition from established players like Pfizer/BioNTech and Moderna. Its competitive advantage lies in its proprietary mRNA technology platform and strategic partnerships.
Total Addressable Market (TAM)
The global mRNA therapeutics and vaccines market is projected to reach hundreds of billions of dollars in the coming years. CureVac NV is positioned to capture a share of this market through its pipeline of mRNA-based products, including vaccines and cancer immunotherapies.
Upturn SWOT Analysis
Strengths
- Pioneering mRNA technology
- Proprietary mRNA technology platform
- Strategic partnerships with GSK and others
- Experienced leadership team
Weaknesses
- Delayed COVID-19 vaccine development
- Lower efficacy compared to competitor vaccines
- High cash burn rate
- Dependence on partnerships for funding and development
Opportunities
- Advancement of second-generation COVID-19 vaccine
- Expansion of mRNA technology into new therapeutic areas
- Potential for breakthrough cancer immunotherapies
- Further strategic partnerships
Threats
- Intense competition from established players
- Regulatory hurdles for new products
- Clinical trial failures
- Funding challenges
Competitors and Market Share
Key Competitors
- BNTX
- MRNA
- LLY
- AZN
- JNJ
Competitive Landscape
CureVac NV faces intense competition from established players with greater resources and approved products. The company's competitive advantage lies in its proprietary mRNA technology platform, but it needs to demonstrate clinical and commercial success to gain market share.
Growth Trajectory and Initiatives
Historical Growth: CureVac NV's historical growth has been characterized by significant investment in research and development. The company has experienced periods of rapid expansion followed by setbacks due to clinical trial results.
Future Projections: Future growth is dependent on the successful development and commercialization of mRNA-based products. Analyst estimates vary widely due to the uncertainty surrounding the company's pipeline.
Recent Initiatives: Recent initiatives include the partnership with GSK for the development of a second-generation COVID-19 vaccine and the advancement of mRNA-based cancer immunotherapies in clinical trials.
Summary
CureVac NV is a pioneer in mRNA technology facing fierce competition. Its initial COVID-19 vaccine setbacks highlight its challenges, but its continued research in cancer immunotherapies and its partnership with GSK present potential growth avenues. The company's financial health is uncertain, and success depends on clinical trial outcomes and successful product commercialization. Investors should carefully assess the company's risk profile due to the volatile nature of the biotech industry.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Investor Relations
- SEC Filings
- Market Research Reports
- Financial News Sources
Disclaimers:
This analysis is based on available information and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a financial advisor. Market share data is estimated and subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About CureVac NV
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2020-08-14 | CEO, MD & Member of Management Board Dr. Alexander Zehnder M.B.A., M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 825 | Website https://www.curevac.com |
Full time employees 825 | Website https://www.curevac.com | ||
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). The company's portfolio includes clinical and preclinical candidates for various disease indications in prophylactic vaccines, oncology, and molecular therapy. It also delivers optimized mRNAs to stimulate the production of therapeutic proteins utilizing its technology and instructs human cells to produce or secrete specific proteins in the nucleus, cytoplasm, cellular organelles, and cell membrane. In addition, the company offers The RNA Printer, a downsized, integrated, and highly automated process for manufacturing of mRNA vaccines and therapeutics. Further, it develops prophylactic vaccine lead candidate that addresses urinary tract infections targeting uropathogenic E. coli (UPEC) bacteria; vaccine candidates CV0601 and CV0701, which are in phase 2 clinical study against SARS-CoV-2; vaccines for off-the-shelf and fully personalized cancer precision immunotherapies in oncology; and CVGBM for treating cancer. Additionally, the company develops, manufactures, and commercializes mRNA vaccines targeting SARS-CoV-2 variants; antigen cancer precision immunotherapy candidate that targets squamous non-small cell lung cancer; and antigen cancer precision immunotherapy candidate CVGBM that is tested in patients with surgically resected MGMT-unmethylated glioblastoma or astrocytoma with a molecular signature of glioblastoma. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.